Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy.

With the simultaneous detection of the CAR-T cells and the B cell malignancy in patient peripheral blood, the HDSCA-HemeCAR workflow may be considered for risk monitoring and patient management.